Revive Therapeutics Ltd
CNSX:RVV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Revive Therapeutics Ltd
Cash from Financing Activities
Revive Therapeutics Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Revive Therapeutics Ltd
CNSX:RVV
|
Cash from Financing Activities
CA$187.9k
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cash from Financing Activities
-$742m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cash from Financing Activities
CA$269.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
21%
|
|
|
Cronos Group Inc
TSX:CRON
|
Cash from Financing Activities
-$19.9m
|
CAGR 3-Years
-90%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cash from Financing Activities
$25.2m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
Revive Therapeutics Ltd
Glance View
Revive Therapeutics Ltd. engages in the research, development, and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid pharmaceuticals markets. The company is headquartered in Toronto, Ontario. The company went IPO on 2013-07-12. The firm is focused on the research and development of therapeutics for infectious diseases and rare disorders. The firm is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
See Also
What is Revive Therapeutics Ltd's Cash from Financing Activities?
Cash from Financing Activities
187.9k
CAD
Based on the financial report for Dec 31, 2025, Revive Therapeutics Ltd's Cash from Financing Activities amounts to 187.9k CAD.
What is Revive Therapeutics Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-53%
Over the last year, the Cash from Financing Activities growth was -90%. The average annual Cash from Financing Activities growth rates for Revive Therapeutics Ltd have been -17% over the past three years , -53% over the past five years .
